InspireMD, Inc.
NSPRInspireMD, Inc. is a medical technology company specializing in the development of innovative devices for the treatment of cardiovascular diseases. The company is known for its proprietary MGuard technology, a embolic protection system designed to reduce the risk of heart attack during percutaneous coronary interventions. InspireMD focuses on providing solutions that improve patient outcomes and procedural safety in interventional cardiology.
Company News
InspireMD's Compensation Committee approved inducement grants of 36,118 restricted shares to one new non-executive employee on January 14, 2026, under the company's 2024 Inducement Plan in compliance with Nasdaq rules. The shares vest over three years subject to continued employment.
InspireMD announced that its C-GUARDIANS pivotal trial results have been published in JACC, demonstrating that the CGuard® Prime Carotid Stent System achieved the lowest 30-day and 1-year major adverse event rates in carotid stenting studies, with a 30-day DSMI rate of 0.95% and 1-year ipsilateral stroke rate of 1.93%. The trial enrolled 316 pat...
InspireMD granted 122,054 shares of restricted stock to eight new non-executive employees under its 2024 Inducement Plan, with shares vesting over a three-year period.
InspireMD reported Q3 2025 financial results, highlighting a 39% revenue increase to $2.5 million, successful U.S. commercial launch of CGuard Prime carotid stent system, and continued global market expansion despite increased operating expenses.
InspireMD granted 40,513 shares of restricted stock to three new non-executive employees under its 2024 Inducement Plan, with shares vesting over a three-year period.
